Canada

 

Alexion is focused on providing innovative treatments to patients with severe and life-threatening rare diseases for which there are few, if any, effective treatment options. In 2009, Alexion began operations in Canada to serve patients locally. We aim to work in partnership with all stakeholders including healthcare providers, patient advocacy organizations and government in order to best serve patients. By expanding the knowledge and awareness of rare diseases, we help the medical community improve the process for diagnosis and treatment. Our goal is to bring hope to patients and families by delivering life-changing therapies.

In Canada, Soliris® has received marketing authorization from Health Canada for all patients with PNH. Soliris is also approved by Health Canada as safe and effective for use in children and adults with atypical HUS to inhibit complement-mediated thrombotic microangiopathy (TMA). To further advance the understanding of PNH and atypical HUS in the Canadian population, Alexion Canada sponsors disease registries that enroll treated and untreated patients who are diagnosed with these conditions. This is our commitment to ongoing research into the rare conditions that our therapies treat.

In addition, Strensiq® (asfotase alfa) is approved in Canada as an enzyme replacement therapy for patients with confirmed diagnosis of paediatric-onset hypophosphatasia under the Notice of Compliance with conditions (NOC/c) policy.

Learn more about Alexion’s research and development efforts.

News

  • Learn More About the PMPRB Hearing with Alexion Canada
  • CADTH Common Drug Review Patient Input
    Patients living with a rare disease face many challenges and often live with little hope and have limited treatment options. Their experiences and perspectives are important to better understanding the disease. From now until November 23, 2017, there is an open call for patient input for the CADTH Common Drug Review of Kanuma (sebelipase alfa) for the treatment of lysosomal acid lipase deficiency (LAL-D). Individuals wishing to contribute to the patient submission should contact Andrew McFadyen of the Isaac Foundation and the Equal Access for Rare Disorders via email or website.


Product Information


Patient Groups and Resources

Local Patient Organizations

Alexion shares key goals with patient organizations worldwide, including increasing the understanding of rare diseases, improving patient care, and enhancing patient access to innovative therapies. Local patient organizations in Canada include:

Metabolic Assistance Program

Alexion offers a Metabolic Assistant Program (MAP), which is a no-charge program that provides education, assistance with access to Strensiq®, and ongoing treatment support for people living with hypophosphatasia, their families and their healthcare providers. To learn more about MAP call 1-844-627-7262 or download the MAP brochure. Download the MAP enrollment form.

OneSource™

Alexion offers OneSource™, a personalized program that provides education, assistance with access, and treatment support for patients and their caregivers. To learn more about OneSource™ call 1-888-765-4747 or download the OneSource™ brochure. Download the OneSource™ enrollment form.

Careers

Working at Alexion is an experience like no other. With a focus on devastating and rare diseases, each endeavor is urgent and every day counts. Groundbreaking innovation, life-saving therapies and a promising pipeline, all driven by a team with a shared sense of purpose and dedication — that's Alexion.

Join us to achieve the impossible and do what’s never been done before.

Browse job openings in Canada or contact:

Human Resources Canada Alexion Pharma Canada Corp.
P: +1 866.393.1188
E: Alexion.Canada@alexion.com